Elevation Point Wealth Partners LLC Acquires 5,370 Shares of Amgen Inc. $AMGN

Elevation Point Wealth Partners LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 626.6% during the third quarter, HoldingsChannel.com reports. The firm owned 6,227 shares of the medical research company’s stock after acquiring an additional 5,370 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Amgen were worth $1,757,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Sequoia Financial Advisors LLC lifted its holdings in shares of Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares during the period. Davis Capital Management purchased a new position in shares of Amgen during the third quarter valued at $1,841,000. D.A. Davidson & CO. raised its holdings in shares of Amgen by 2.6% in the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares in the last quarter. Global Wealth Management Investment Advisory Inc. raised its holdings in shares of Amgen by 56.2% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after acquiring an additional 4,699 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Amgen by 18.2% in the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after acquiring an additional 6,115 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Stock Performance

AMGN stock opened at $366.21 on Monday. The firm has a market cap of $197.41 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 3.63 and a beta of 0.45. The firm has a 50-day simple moving average of $357.73 and a two-hundred day simple moving average of $325.68. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Analyst Ratings Changes

AMGN has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Royal Bank Of Canada upped their price target on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Truist Financial increased their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. The Goldman Sachs Group lifted their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Finally, Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.